Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marija Radak-Perovic is active.

Publication


Featured researches published by Marija Radak-Perovic.


Annals of the Rheumatic Diseases | 2017

AB1149 The ability of the health system to identify the burden of rheumatoid arthritis in serbia: a eular survey

Mirjana Zlatkovic-Svenda; Roksanda Stojanovic; Sandra Sipetic-Grujicic; Marija Radak-Perovic; Nemanja Damjanov; Francis Guillemin

Objectives to estimate the rheumatoid arthritis (RA) prevalence in two urban regions of Serbia, covering the northern and the southern part, under the European League Against Rheumatism (EULAR) prevalence survey; to assess the ability of the health system to recognize and treat patients with RA. Methods The survey was conducted in four Serbian towns: Belgrade in the north and three towns in the south: Cacak (Moravicki region), Uzice (Zlatiborski region) and Krusevac (Rasinski region), covering 36.5% of the total Serbian population with more than 99% Caucasians, mostly orthodox Serbs (83%), <4% Hungarians, Roms and Bosnians and a minority of other nationalities. The first-detection phase of the study comprised previously translated and validated telephone Questionnaire usage with 33 items covering signs, symptoms, self-reported diagnosis and classification criteria for RA (ACR 1987) (1). Diagnoses were confirmed by rheumatologists in a second-confirmation phase. Prevalence results were standardized for age and sex with regard to Serbian population (national census 2002). Confirmed RA cases were asked two more questions: “How long had you had symptoms before you were given the diagnosis of RA” and “How had you been treated for that period of time”. Results 6213 people were contacted and 63.6% answered the survey; joint pain was reported by 1,799 persons, and joint pain accompanied with joint swelling by 606 persons. A total of 23 RA cases were identified; 2 newly diagnosed. The standardized RA prevalence estimates were 0.30% (95% confidence interval [95% CI] 0.09;0.51) for the north, e.g. 0.09 (95% CI 0.08;0.26) for men and 0.49% (95% CI 0.19;0.79) for women. RA prevalence estimates were 0.42% (0.12;0.72) for the south; 0.28 (0.00;0.56) for men and 0.55% (0.09;1.00) for women, with the female to male ratio 5,5:1 in the north and 2:1 in the south. Time period from the first symptoms occurence to the RA diagnosis was 17.7 (13.2) months for the northern part and 25.0 (16.9) for the southern; 20.6 (14.9) for Serbia; in that period patients were mostly treated with NSAIDS (82%) and physical therapy (30%); short-lasting corticosteroids were given to 13%, peroral corticosteroids to 4% and no patients were treated with DMARDS. Conclusions RA prevalence in the southern and northern part of Serbia is in line (0.42% [95% CI 0.12;0.72]) vs 0.30% [95% CI 0.09;0.51]), being more frequently presented in females as compared to males (five times more in the north and two times more in the south). Delay in diagnosis as compared to the first symptoms occurence was 21 months and during that time no patients were treated with DMARDS. References Zlatkovic-Svenda MI, Stojanovic RM, Milenkovic MP, Vlajinac HD, Le Bihan E, Guillemin F. Adaptation and validation of a telephone questionnaire – Serbian version for case detection of rheumatoid arthritis and spondyloarthropathy (multicentric Eular study). Clin Exp Rheumatol. 2007;25 (1): 75–84. Disclosure of Interest None declared


Phytotherapy Research | 2016

Dry Olive Leaf Extract in Combination with Methotrexate Reduces Cell Damage in Early Rheumatoid Arthritis Patients—A Pilot Study

Andrea Čabarkapa; Lada Živković; Sunčica Borozan; Mirjana Zlatkovic-Svenda; Dragana Dekanski; Ivan Jančić; Marija Radak-Perovic; Vladan Bajic; Biljana Spremo-Potparevic

The effects of co‐administration of dry olive leaf extract (DOLE) with standard methotrexate (MTX) therapy on the parameters of cell damage and inflammation in patients with early and long‐term rheumatoid arthritis (RA) were evaluated at baseline, 3 and 6 weeks. Patients were assigned to groups: the early phase RA group on MTX monotherapy (E MTX), and the two RA groups that received co‐treatment with DOLE and MTX: early (E MTX + DOLE) and long‐term phase patients (L‐t MTX+ DOLE). Baseline values indicated increased parameters of cell damage and disruption of redox balance in all groups. After three weeks the E MTX + DOLE group maintained high catalase activity, exhibited decrease of lipid peroxidation and protein damage indicators—thiols and nitrites, while levels of DNA damage and pro‐inflammatory interleukin‐6 were significantly reduced. In E MTX group catalase activity remained unaltered while significant lipid peroxidation and DNA damage reductions were seen only after six weeks. L‐t MTX + DOLE group showed only modest alterations of cell damage parameters during six weeks. Combined administration of DOLE with MTX contributes to faster reduction of cell damage, restores oxidative balance and improves interleukin‐6 suppression during high disease activity in early phase RA, but not in long term patients. Copyright


Annals of the Rheumatic Diseases | 2015

THU0358 The Ability of the Health System to Identify the Burden of Spondyloarthritis in Two Regions of Serbia: A Eular Survey

Mirjana Zlatkovic-Svenda; Roksanda Stojanovic; Sandra Sipetic-Grujicic; Marija Radak-Perovic; Nemanja Damjanov; Francis Guillemin

Objectives To determine spondyloarthritis (SpA) prevalence in two different regions of Serbia, as part of the European League Against Rheumatism (EULAR) prevalence survey; to assess the ability of the health system to identify and treat patients with SpA. Methods Survey comprised a two-stage approach with a sample of urban population in 2 areas: Belgrade, located in the north and Cacak, Uzice and Krusevac in the south, covering 36.5% of the total Serbian population. In a detection phase, every 100-th telephone number was contacted to answer a previously validated screening telephone questionnaire. Confirmation of cases was by contact with the patients rheumatologist or rheumatological examination. Prevalence results were standardized for age and sex according to Serbian population (national census 2002). Confirmed SpA cases were asked two more questions: “How long had you had symptoms before you were given the diagnosis of SpA” and “How had you been treated for that period of time”. Results 6213 people were contacted; 63.6% answered the survey; 66 were examined. A total of 16 SpA cases were identified (5 newly diagnosed). The standardized SpA prevalence for the north was 0.28% (95% confidence interval [95% CI] 0.08;0.48); 0.31 (95% CI 0.00;0.65) for men and 0.25% (95% CI 0.01;0.49) for women; for the south 0.42% (0.02;0.82); 0.41 (0.02;0.81) for men and 0.43% (0.04;0.82) for women. Mean (SD) time (months) to SpA diagnosis was 23.6 (24.9) for the north and 13.6 (11.3) for the south; 19.2 (20.2) for Serbia. Before they were given the SpA diagnosis, all patients were treated with NSAIDS, but mostly “on demand” (56.2%), some of them with physical therapy (43.7%) and benzodiazepins (18.7%). Conclusions SpA prevalence in Serbia does not differ much between southern and northern part of the country as well as between women and men. Diagnostic delay for SpA is 19 months and most of the patients were inadequately treated for that period of time. One third of the revealed SpA cases were not diagnosed previously. Disclosure of Interest None declared


Annals of the Rheumatic Diseases | 2015

Prevalence of spondyloarthritis in Serbia: a EULAR endorsed study

Mirjana Zlatkovic-Svenda; Roksanda Stojanovic; Sandra Sipetic-Grujicic; Marija Radak-Perovic; Nemanja Damjanov; Francis Guillemin

In order to determine the burden of inflammatory rheumatic diseases across Europe, the European League Against Rheumatism (EULAR) unique-methodology prevalence survey of rheumatoid arthritis (RA) and spondyloarthritis (SpA) was carried out in several European countries, including Serbia. Aiming to enable comparable results, it comprised a common two-stage approach: a detection phase (validated screening telephone questionnaire, primarily tested in France1 ,2) and a confirmation phase (according to a certified rheumatologist or, for previously non-diagnosed cases, a rheumatology examination). The Serbian SpA prevalence survey was conducted by 30 trained interviewers on urban population in four Serbian towns: Belgrade (north), and Cacak, Krusevac and Užice (south), by telephone (every 100th telephone number) from April to October 2008. The sample covered 36.5% of the total Serbian population with more than 99% Caucasians, mostly orthodox Serbs (83%), <4% Hungarians, Gypsies and Bosnians and a minority of other nationalities. Respondents were asked whether they have (or …


Radiation Protection Dosimetry | 2013

Screen-film versus digital radiography of sacroiliac joints: evaluation of image quality and dose to patients

Dragoslav Jablanović; Olivera Ciraj-Bjelac; Nemanja Damjanov; Srdjan Seric; Marija Radak-Perovic; Danijela Arandjic; Ruzica Maksimovic

The purpose of this paper is to evaluate the image quality and dose to patients in the radiography of sacroiliac joints and to perform a clinical comparative study of digital and conventional screen-film radiography. Routine radiography of sacroiliac joint was performed in 60 patients using digital and screen-film radiography. The visibility of five anatomical regions and the overall image quality were rated by experienced radiologists. Patient dose assessment in terms of entrance surface air kerma (ESAK) was performed. The digital system showed slightly improved visualisation of specific anatomical structures. Overall image quality was significantly better in the digital when compared with the screen-film imaging system. The average ESAK was 2.4 mGy in screen-film and 3.6 mGy in digital radiography. The digital radiography provided equal or better visibility of anatomical details and overall image quality, but on higher dose levels. Therefore, the practice on digital systems must be optimised.


Annals of the Rheumatic Diseases | 2013

AB0638 Metabolic syndrome characteristics in patients with primary gout

Marija Radak-Perovic; M. I. Zlatkovic-Svenda; M. M. Zlatanovic; M. M. Sefik-Bukilica; M. M. Terek; T. V. Radnic-Zivanovic

Background The association between gout and obesity, dyslipidaemia, hypertension and hyperglycaemia is a well-known fact. The presence of most of these abnormalities in the same patient is termed as metabolic syndrome (MetS). MetS increases the risk and the mortality of atherosclerotic cardiovasular diseases (CVDs). In patients with gout the prevalence of MetS is 30% to 82%. Objectives To determine the prevalence of MetS and to examine the association between non-abdominal/abdominal obesity and the components of MetS in patients with primary gout. BMI/ waist circumference (WC) are anthropometric measurements used as indices of total and abdominal obesity. Methods A total of 81 pts with primary (ACR) gout, 95.1% males, underwent physical examination and blood tests. The original National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III were used to define MetS. Patients with three or more of the following criteria were defined as having MetS: abdominal obesity (WC≥102cm for men; ≥88cm for women), high TG (≥1,69mmol/L), low HDL(<1, o4mmol/L for men, and <1,29mmol/L for women), high blood pressure (≥135/85mmHg) and high fasting glucosae (≥6,1mmol/L). Patients currently taking antihypertensive or hypoglycaemic drugs met the criteria for high blood pressure or high FG. According to WHO, obesity was defined as BMI of ≥ 30kg/m2. Results The frequency of the individual items of MetS were: WC ≥102cm, 33 (40.7%); blood pressure ≥135/85 mmHg, 61 (75.3%); glucosae≥ 6,1, 32 (39.5%); HDL <1,04mmol/l, 36 (44.4%); triglicerydes ≥1,69, 48 (59.3%). The BMI ≥30kg/m2 was found in 20(28.4%). The prevalence of MetS in pts with gout was 56.8% and it increased with age (from 48.7% in pts younger than 60 years to 64.3% in pts aged 60 and more). Subjects with MetS had higher SUA and sera creatinin leveles than those without MetS, but without statistically significant difference. BMI positively correlated with HTA and hypercholesterolemia (p=0.015 and p=0.041, respectively), and WC positively correlated with HTA (p=0.003). Conclusions: 1.Our data has shown high prevalence of MetS among gouty pts 2.Correlations between BMI and the components of MetS were similar to those of WC implicating the appropriateness of using either of antropometric measures as indices of obesity in clinical practice 3. Management of obesity should be emphasized to correct metabolic abnormalities in gouty patients. Disclosure of Interest None Declared


Annals of the Rheumatic Diseases | 2013

SAT0201 Relationship of Matrix Metalloproteinase-3 With Pulmonary and Joint Involvement in Scl-70 Positive Systemic Sclerosis Patients

M. Zlatanovic; Mirjana Sefik-Bukilica; P. Ostojic; S.Z. Prodanovic; S. Seric; Goran Radunovic; Marija Radak-Perovic; Nemanja Damjanov

Background Extracellular matrix degradation is regulated mainly by matrixmetalloproteinases (MMPs). MMP-3 can degrade many components of the extracellular matrix and an increase in serum MMP-3 concentration has been proposed as a synovial derived marker of inflammation. Objectives To determine matrix metalloproteinase-3 (MMP-3) serum levels in anti Scl 70 positive patients with systemic sclerosis (SSc) and to study clinical significance and the relationship between MMP-3 and pulmonary and joint involvement Methods Forty-seven anti-Scl 70 antibodies positive patients with systemic sclerosis (43 female, 4 male) and 50 healthy controls were included in the study. All SSc patients underwent standard assessment, including laboratory tests, physical examination with joint assessment, chest X-ray and pulmonary functional tests, including diffusion capacity for carbon monoxide (DLco) and forced vital capacity (FVC). Levels of MMP-3 were measured with specific ELISA kit (Aeskulisa DF) with normal range between 18-60 ng/ml for female and 24-120ng/ml for male. Results SSc patients had significantly higher MMP-3 concentration compared to healthy donors 122.64±188.40 vs. 57.4±46.79, p<0.001. Twenty-two (46.8%) SSs pts had increased MMP-3 levels above normal range and those had more frequently pulmonary fibrosis (p<0.001) and arthritis (p<0.001). Patients with increased levels of MMP-3 had significantly more frequently reduction in DLco <75% predicted (p<0.001). Conclusions In 47 patient with systemic sclerosis and anti-Scl 70 positive antibodies, high levels of MMP-3 significantly positively correlate with pulmonary fibrosis, DLCo < 75% predicted and joint involvement (arthritis). Disclosure of Interest None Declared


Srpski Arhiv Za Celokupno Lekarstvo | 2012

Quality of treatment in gouty patients considering EULAR recommendations

Marija Radak-Perovic; Mirjana Zlatkovic-Svenda

INTRODUCTION There are 12 recommendations for gout treatment, based on evidence and opinion of experts. OBJECTIVE To assess the quality of therapy in patients with gout analyzing adherence to four selected recommendations. METHODS Retrospective cross sectional study of 111 patients with gouty flare was conducted. Adherence to selected recommendation was defined as odds ratio between the number of patients whose therapy adhered to treatment recommendation and the number of patients eligible for the relevant recommendation. These recommendations refer to indications for allopurinol treatment (R1), prophylaxis of induced gouty flares in the first month of allopurinol treatment (R2), treatment goals (R3), and treatment monitoring regime (R4). RESULTS Out of 111 patients with gout, 25 with tophi, 87 with frequent gouty flares and 46 with CUA or X-ray erosions were indicated for allopurinol treatment. The adherence to R1 was 76% for tophi patients, 54% for patients with frequent gouty flares, and 63% for patients with CUA. None of the patients starting allopurinol was either recruited for gouty prophylaxis or monitored properly; adherence to R2 as well as to R4 was 0%. Target serum uric acid (SUc) rating below 360 micromol/L was achieved in 13/50 patients treated with allopurinol, while the adherence to R3 was 26%. Therapeutic monitoring in accordance with P4 was not done in any of the patients on allopurinol. There were no differences in mean levels of the SUc between allopurinol users and non-users: 471.3 +/- 164.4 vs. 460.0 +/- 103.5 micromol/L (p = 0.067). Therefore, almost every second patient with gouty flares was on allopurinol therapy (50/111). CONCLUSION The degree of deviation in relation to the key principles of correct treatment in patients with gout ranged from a relatively high (24%) to that of absolute digression (100%).


Clinical Rheumatology | 2013

Late-onset systemic lupus erythematosus: clinical features, course, and prognosis

Aleksandra Tomic-Lucic; Radmila Petrovic; Marija Radak-Perovic; Dragan R. Milovanovic; Jasmina R. Milovanovic; Sandra Zivanovic; Suzana Pantovic; Mirjana Veselinovic


Rheumatology | 2013

High prevalence of autoimmune thyroid disease in subjects with sicca symptoms without Sjögren’s syndrome

Vera Milic; Goran Radunovic; Ivan Boricic; Sanja Ognjanovic; Radmila Petrovic; Marija Radak-Perovic; Nada Vujasinovic-Stupar; Nemanja Damjanov

Collaboration


Dive into the Marija Radak-Perovic's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge